Patent ID: 11964944
Assignee: THE UNIVERSITY OF SHEFFIELD
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 16:
17. An invention selected from the group consisting of:
(a) a method for monitoring treatment of an apicomplexan parasitic infection, such as T. gondii infection (including but not limited to any of the treatment of claim 16), comprising monitoring expression, protein in serum or plasma, and/or activity of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of the markers listed in FIGS. 1-2 in a subject (such as a human subject) being treated for an apicomplexan parasitic infection, wherein a decrease or increase in expression and/or presence and/or activity of the one or more markers indicates that the treatment is effective;
(b) a cell line infected with an apicomplexan parasite, wherein the apicomplexan parasite genome comprises a gene encoding an Apetela 2 IV-4 protein with an M=>I modification at residue 570 (“AP2 IV-4 M570I”) compared to its orthologous gene on the reference T. gondii ME49 strain (gene ID: TGME49_318470);
(c) a method for treating an apicomplexan parasite infection (such as a T. gondii infection), comprising administering to a subject in need thereof an amount effective to treat the infection of an inhibitor (of up-regulated genes) or an activator (of down-regulated genes) of 1 or more of the up-regulated genes listed in FIG. 1 or FIG. 2;
(d) a method for identifying test compounds for apicomplexan parasite therapy, comprising identifying test compounds that reduce expression (for up-regulated genes), or increase expression (for down-regulated genes) of 1 or more of the apicomplexan parasite genes in FIGS. 3-5;
(e) a plurality of isolated probes that in total selectively bind to at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 500, or all of the markers listed in FIGS. 3-5, complements thereof, or their expression products, or functional equivalents thereof wherein at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or all of the probes in total are selective for markers that are upregulated in the EGS strain of T. gondii after infection of human fibroblasts, human neuronal stem cells or human monocytic lineage cells;
(f) a plurality of isolated probes that in total selectively bind to at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 500, or all of the markers listed in FIG. 1-2, complements thereof, or their expression products, or functional equivalents thereof, wherein at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or all of the probes in total are selective for markers that are upregulated in human fibroblasts, human neuronal stem cells or human monocytic lineage cells after infection with T. gondii, including but not limited to infection with the EGS strain of T. gondi.